99365-69-2

Basic information

• Product Name: 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE
• Synonyms: 7-NITRO-1,2,3,4-TETRAHYDROISOQUINOLINE HCL;7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE;7-Nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride, 97+%;1,2,3,4-tetrahydro-7-nitroisoquinoline hydrochloride;Isoquinoline,1,2,3,4-tetrahydro-7-nitro-, hydrochloride (1:1)
• CAS NO: 99365-69-2
• Molecular Formula: C₉H₁₀N₂O₂*ClH
• Molecular Weight: 214.65
• Product Categories: pharmacetical
• Mol File: 99365-69-2.mol
• Article Data: 17

Chemical Properties

• Melting Point: 214-216 °C(Solv: methanol (67-56-1))
• Boiling Point: 349 °C at 760 mmHg
• Flash Point: 164.9 °C
• Appearance: /
• Vapor Pressure: 3.41E-05mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE(99365-69-2)
• EPA Substance Registry System: 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE(99365-69-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 99365-69-2(Hazardous Substances Data)

Usage

General Description

7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE is a chemical compound that consists of a nitro group attached to a tetrahydro-isoquinoline ring structure and is present in the form of a hydrochloride salt. It is used primarily in scientific research and drug development, particularly in the study of neuropharmacology and the development of potential medications for conditions such as Parkinson's disease and drug addiction. The compound has been found to have potential therapeutic effects on the central nervous system due to its interactions with specific receptors and neurotransmitters. Additionally, 7-NITRO-1,2,3,4-TETRAHYDRO-ISOQUINOLINE HYDROCHLORIDE has been studied for its potential use in the treatment of pain and as an analgesic.

InChI:InChI=1/C9H10N2O2.ClH/c12-11(13)9-2-1-7-3-4-10-6-8(7)5-9;/h1-2,5,10H,3-4,6H2;1H

Upstream product

• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 1336-21-6 ammonium hydroxide 
• 42923-79-5 7-nitro-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 175871-45-1 7-amino-1,2,3,4-tetrahydroisoquinoline dihydrochloride 
• 171049-42-6 tert-butyl 3,4-dihydro-7-nitroisoquinoline-2(1H)-carboxylate 
• 14097-35-9 2-methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline 
• 1072084-79-7 7-(4-chloro-6-morpholin-4-yl-pyrimidin-2-ylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1354719-15-5 2-[3-(1,2,3,4-tetrahydro-isoquinolin-7-ylcarbamoyl)-phenyl]-pyrrolidine-1-carboxylic acid (3-cyano-phenyl)-amide trifluoroacetate 
• 1354721-19-9 7-{3-[1-(3-cyanophenylcarbamoyl)-pyrrolidin-2-yl]-benzoylamino}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1354719-12-2 3-[1-(3,4-dimethoxy-benzoyl)-pyrrolidin-2-yl]-N-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-benzamide trifluoroacetate 
• 1354721-18-8 7-{3-[1-(3,4-dimethoxy-benzoyl)-pyrrolidin-2-yl]-benzoylamino}-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 1354721-17-7 7-(3-pyrrolidin-2-ylbenzoylamino)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester hydrochloride 
• 1354721-16-6 7-[3-(1-tert-butoxycarbonyl-pyrrolidin-2-yl)-benzoylamino]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid benzyl ester 
• 787640-41-9 benzyl 7-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1301134-22-4 N-(3-(3-(2-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)phenyl)-N'-phenylurea 
• 1301134-19-9 2,6-difluoro-N-(3-(3-(2-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrimidin-4-yl)imidazo[1,2-a]pyridin-2-yl)phenyl)benzamide 
• 1301138-49-7 C₂₇H₂₅N₇ 

Relevant articles and documents

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

A structure-activity analysis of biased agonism at the dopamine D2 receptor

Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs. A number of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia. As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor. We have generated SAR based on a novel D2R partial agonist, tert-butyl (trans-4-(2-(3,4-dihydroisoquinolin- 2(1H)-yl)ethyl)cyclohexyl)carbamate (4). This ligand shares structural similarity to cariprazine (2), a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points. We synthesized a number of derivatives of 4 with subtle structural modifications, including incorporation of cariprazine fragments. By combining pharmacological profiling with analytical methodology to identify and to quantify bias, we have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group containing the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.